Latest & greatest articles for benztropine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on benztropine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on benztropine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for benztropine

1. Tenofovir reduces mother-to-child hepatitis B transmission

Tenofovir reduces mother-to-child hepatitis B transmission Signal - Tenofovir reduces mother-to-child hepatitis B transmission Dissemination Centre Discover Portal NIHR DC Discover Tenofovir reduces mother-to-child hepatitis B transmission Published on 25 July 2017 Giving pregnant women with hepatitis B the drug tenofovir reduced the likelihood of passing the infection on to their baby by about 80% and did not have any adverse impact on mother or child. Hepatitis B often doesn't cause any (...) obvious symptoms in adults and typically passes in a few months without treatment, but in children it often persists for years and may cause progressive liver damage with cirrhosis and increased risk of liver cancer. Babies can get the infection from their mother during birth. The findings of this systematic review support current NICE recommendations that pregnant women with active hepatitis B infection are treated in the third trimester using the drug tenofovir and at risk babies immunised after

2019 NIHR Dissemination Centre

2. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study 30504445 2019 01 11 1468-2060 78 2 2019 Feb Annals of the rheumatic diseases Ann. Rheum. Dis. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. 179-185 10.1136/annrheumdis-2017-212763 We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced (...) infusion of 1000 mg rituximab significantly delays the development of arthritis in subjects at risk of developing RA, providing evidence for the pathogenetic role of B cells in the earliest, prearthritis stage of autoantibody positive RA. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. Gerlag Danielle M DM Department of Clinical immunology and Rheumatology, Amsterdam Rheumatology and Immunology Center

2019 EvidenceUpdates

3. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Tisagenlecleucel for treating relapsed or Tisagenlecleucel for treating relapsed or refr refractory B-cell acute lymphoblastic actory B-cell acute lymphoblastic leukaemia in people aged up to 25 y leukaemia in people aged up to 25 years ears T echnology appraisal guidance Published: 21 December 2018 nice.org.uk/guidance/ta554 © NICE 2019. All rights reserved. Subject to Notice (...) . They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) guidance on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, November 2018 PDF Print ISBN 978-92-9498-286-5 ISBN 978-92-9498-294-0 DOI 10.2900/79127 DOI 10.2900/489464 Catalogue number TQ-06-18-328-EN-N Catalogue number TQ-06-18-328-EN-C © European Centre for Disease Prevention and Control, 2018 Cover picture: © iStock Reproduction is authorised, provided the source is acknowledged. For any use or reproduction of photos or other material

2019 European Centre for Disease Prevention and Control - Public Health Guidance

5. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

6. The management of primary mediastinal B?cell lymphoma: Good Practice Paper

The management of primary mediastinal B?cell lymphoma: Good Practice Paper The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice Paper - Cwynarski - - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free Access (...) The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice Paper Department of Haematology, University College London Hospitals NHS Foundation Trust, , London, UK Department of Haematology, University College London Hospitals NHS Foundation Trust, , London, UK King's College London and Guy's and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, , London, UK Department of Haematology

2019 British Committee for Standards in Haematology

7. Diagnosis and management of primary central nervous system diffuse large B?cell lymphoma

Diagnosis and management of primary central nervous system diffuse large B?cell lymphoma Guidelines for the diagnosis and management of primary central nervous system diffuse large B‐cell lymphoma - Fox - - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free (...) Access Guidelines for the diagnosis and management of primary central nervous system diffuse large B‐cell lymphoma Clinical Haematology, Nottingham University Hospitals NHS Trust, , Nottingham, UK Department of Haematology, University College Hospital, , London, UK Department of Haematology, Division of Cancer Sciences, School of Medical Sciences, Aintree Hospital NHS Trust, , Liverpool, UK University of Manchester, , Manchester, UK Velindre Cancer Centre, , Cardiff, UK Department of Haematology

2018 British Committee for Standards in Haematology

8. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (PubMed)

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted (...) an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were

2018 NEJM

9. Chronic hepatitis B virus infection. (PubMed)

Chronic hepatitis B virus infection. Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical (...) . With current vaccines, therapies, and an emphasis on improving linkage to care, WHO's goal of eliminating hepatitis B virus as a global health threat by 2030 is achievable.

2018 Lancet

10. Nonacog beta pegol (haemophilia B) ? Benefit assessment according to §35a Social Code Book V

Nonacog beta pegol (haemophilia B) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nonacog beta pegol (Hämophilie B) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 26 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-57 (...) Nonacog beta pegol (haemophilia B) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-57 Version 1.0 Nonacog beta pegol (haemophilia B) 26 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nonacog beta pegol (haemophilia B) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B (PubMed)

Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B 30355579 2018 12 07 2473-9537 2 21 2018 Nov 13 Blood advances Blood Adv Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B. 2798-2810 10.1182/bloodadvances.2018019950 Precursor B-cell acute lymphoblastic leukemia (B-ALL) is associated with recurrent mutations that occur in cancer-initiating cells. There is a need to understand how (...) driver mutations influence clonal evolution of leukemia. The E26-transformation-specific (ETS) transcription factors PU.1 and Spi-B (encoded by Spi1 and Spib ) execute a critical role in B-cell development and serve as complementary tumor suppressors. Here, we used a mouse model to conditionally delete Spi1 and Spib genes in developing B cells. These mice developed B-ALL with a median time to euthanasia of 18 weeks. We performed RNA and whole-exome sequencing (WES) on leukemias isolated from Mb1

Full Text available with Trip Pro

2018 Blood advances

12. Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell–mediated remissions (PubMed)

Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell–mediated remissions 30301812 2018 11 14 2473-9537 2 19 2018 Oct 09 Blood advances Blood Adv Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions. 2568-2580 10.1182/bloodadvances.2018023119 Conventional local tumor irradiation (LTI), delivered in small daily doses over several weeks, is used clinically as a palliative, rather than (...) curative, treatment for chemotherapy-resistant diffuse large B-cell lymphoma (DLBCL) for patients who are ineligible for hematopoietic cell transplantation. Our goal was to test the hypothesis that accelerated, but not conventional, LTI would be more curative by inducing T cell-mediated durable remissions. We irradiated subcutaneous A20 and BL3750 lymphoma tumors in mice with a clinically relevant total radiation dose of 30 Gy LTI, delivered in 10 doses of 3 Gy over 4 days (accelerated irradiation

Full Text available with Trip Pro

2018 Blood advances

13. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. (PubMed)

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B (...) hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B

2018 JAMA

14. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia Inotuzumab ozogamicin for treating Inotuzumab ozogamicin for treating relapsed or refr relapsed or refractory B-cell acute actory B-cell acute lymphoblastic leukaemia lymphoblastic leukaemia T echnology appraisal guidance Published: 19 September 2018 nice.org.uk/guidance/ta541 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541) © NICE 2018. All rights reserved. Subject to Notice of rights (https

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

15. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les (...) Médicaments VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Substance active (DCI) vaccin diphtérique, tétanique, coquelucheux (acellulaire, multicomposé), de l'hépatite B (ADNr), poliomyélitique (inactivé) et conjugué de l'Haemophilus de type b (adsorbé) INFECTIOLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 11 octobre 2017 Pas d’avantage clinique démontré pour la primovaccination et le

2018 Haute Autorite de sante

16. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras (PubMed)

Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras 30266823 2018 11 14 2473-9537 2 19 2018 Oct 09 Blood advances Blood Adv Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras . 2478-2490 10.1182/bloodadvances.2018021592 Infant B-cell acute lymphoblastic leukemias (B-ALLs) that harbor MLL-AF4 rearrangements are associated with a poor prognosis. One (...) important obstacle to progress for this patient population is the lack of immunocompetent models that faithfully recapitulate the short latency and aggressiveness of this disease. Recent whole-genome sequencing of MLL-AF4 B-ALL samples revealed a high frequency of activating RAS mutations; however, single-agent targeting of downstream effectors of the RAS pathway in these mutated MLL- r B-ALLs has demonstrated limited and nondurable antileukemic effects. Here, we demonstrate that the expression

Full Text available with Trip Pro

2018 Blood advances

17. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis (PubMed)

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis 30254104 2018 11 14 2473-9537 2 18 2018 Sep 25 Blood advances Blood Adv A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. 2400-2411 10.1182/bloodadvances.2018018564 Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools (...) that can help us to understand the disease and optimize therapy. Here we propose a new subtyping of myeloma plasma cells (PCs) from diagnostic samples, assigned by normal B-cell subset associated g ene signatures (BAGS). For this purpose, we combined fluorescence-activated cell sorting and gene expression profiles from normal bone marrow (BM) Pre-BI, Pre-BII, immature, naïve, memory, and PC subsets to generate BAGS for assignment of normal BM subtypes in diagnostic samples. The impact of the subtypes

Full Text available with Trip Pro

2018 Blood advances

18. Exploring the acceptability of Option B plus among HIV-positive Nigerian women engaged and not engaged in the prevention of mother-to-child transmission of HIV cascade: a qualitative study (PubMed)

Exploring the acceptability of Option B plus among HIV-positive Nigerian women engaged and not engaged in the prevention of mother-to-child transmission of HIV cascade: a qualitative study 30253709 2018 12 14 2018 12 14 1813-4424 15 1 2018 12 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance SAHARA J Exploring the acceptability of Option B plus among HIV-positive Nigerian women engaged and not engaged in the prevention of mother-to-child transmission of HIV cascade: a (...) qualitative study. 128-137 10.1080/17290376.2018.1527245 The acceptability of lifelong antiretroviral therapy (ART) among HIV-positive women in high-burden Nigeria, is not well-known. We explored readiness of users and providers of prevention of mother-to-child transmission of HIV (PMTCT) services to accept lifelong ART -before Option B plus was implemented in Nigeria. We conducted 142 key informant interviews among 100 PMTCT users (25 pregnant-newly-diagnosed, 26 pregnant-in-care, 28 lost-to-follow-up

Full Text available with Trip Pro

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

19. Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis (PubMed)

Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis 30288470 2018 11 14 2471-254X 2 10 2018 Oct Hepatology communications Hepatol Commun Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. 1160-1167 10.1002/hep4.1247 Successful treatment outcomes for chronic hepatitis B virus (HBV) infection requires high levels of adherence to treatment. We searched three

Full Text available with Trip Pro

2018 Hepatology communications

20. Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality (PubMed)

Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality 30271878 2018 11 14 2379-5077 3 5 2018 Sep-Oct mSystems mSystems Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. e00081-18 10.1128/mSystems.00081-18 Epstein-Barr virus (EBV) is convincingly associated with gastric cancer, nasopharyngeal carcinoma, and certain lymphomas, but its role in other cancer types remains controversial. To test the hypothesis that there are additional cancer types with high prevalence (...) of EBV, we determined EBV viral expression in all the Cancer Genome Atlas Project (TCGA) mRNA sequencing (mRNA-seq) samples ( n = 10,396) from 32 different tumor types. We found that EBV was present in gastric adenocarcinoma and lymphoma, as expected, and was also present in >5% of samples in 10 additional tumor types. For most samples, EBV transcript levels were low, which suggests that EBV was likely present due to infected infiltrating B cells. In order to determine if there was a difference

Full Text available with Trip Pro

2018 mSystems